Equity Research
William Blair research analyst Matt Larew was featured in MedCity News’ coverage of the acquisition of Abcam by the Danaher corporation.
The pricing for the acquired company as a result of an activist campaign was akin to “planting a flashing neon for-sale sign in the front yard,” Larew wrote in his note.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.
Read moreWilliam Blair initiated research coverage of On Holding AG (ONON $32.87), a fast-growing performance and lifestyle brand based in Switzerland selling athletic footwear, primarily in running, but with a growing presence in newer categories and apparel.
Read moreWilliam Blair initiated research coverage of Cullinan Oncology, Inc. (CGEM $17.37), a company focused on advancing modality-agnostic targeted therapies for cancer, with a broad pipeline encompassing small molecules and multifunctional therapies across a diverse range of oncologic targets.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
